Skip to main content
Figure 3 | Respiratory Research

Figure 3

From: Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts

Figure 3

Indacaterol and roflumilast increased pCREB in a PKA-dependent manner. NHLF were treated with compound (30 min) (A), or pretreated with - (open bars) or + H89 (hatched bars) followed by compound treatment (30 min) (B), and MFI for pCREB determined. Data is reported as percentage of vehicle control, mean ± SEM from n = 4-6 experiments. ROF: roflumilast, INDA: indacaterol. * p < 0.05, **p < 0.01, ***p < 0.001 compared to vehicle treated cells, &p < 0.05 as compared to H89 negative control.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us